Shopping Cart
Remove All
Your shopping cart is currently empty
Lumasiran (ALN-G01), a siRNAproduct, targets glycolate oxidase to inhibit hepatic oxalate production. By silencing the gene encoding glycolate oxidase, Lumasiran depletes the enzyme, preventing the synthesis of oxalate, a toxic metabolite directly linked to the clinical manifestations of Primary hyperoxaluria type 1 (PH1).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $159 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $411 | 2-4 weeks | 2-4 weeks | |
| 10 mg | $642 | 2-4 weeks | 2-4 weeks |
| Description | Lumasiran (ALN-G01), a siRNAproduct, targets glycolate oxidase to inhibit hepatic oxalate production. By silencing the gene encoding glycolate oxidase, Lumasiran depletes the enzyme, preventing the synthesis of oxalate, a toxic metabolite directly linked to the clinical manifestations of Primary hyperoxaluria type 1 (PH1). |
| In vitro | Lumasiran effectively decreased the excretion of urinary oxalate, which is responsible for the progression of kidney failure in patients with Primary Hyperoxaluria Type 1 (PH1)[1]. |
| In vivo | Lumasiran sodium is a subcutaneously administered, liver-directed RNA interference (RNAi) therapeutic agent[2]. |
| Synonyms | ALN-G01 |
| Cas No. | 1834610-13-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.